Safety and Feasibility of Dasatinib and Quercetin in Adults at Risk for Alzheimer's Disease

• Status: Recruiting
• Trial end date: 2023-06-01
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this pilot study is to demonstrate the safety and feasibility of administering intermittent doses of Dasatinib and Quercetin (D+Q) in older adults at risk of Alzheimer's disease (AD). The study will evaluate whether giving D+Q may improve cerebral blood flow regulation, mobility, and cognition in older adults, and thus may prevent progression to Alzheimer's disease.

• Phase: Phase 1/Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Lew Lipsitz
• Treatments: Dasatinib; Quercetin

Criteria

Inclusion Criteria:

• Ambulatory,

• Community dwelling,

• Slow gait speed (<1 m/second),

• Mild Cognitive Impairment (Telephone MoCA score <19, which is indicative of cognitive impairment)

Exclusion Criteria, or as per clinical judgment:

• Telephone MoCA score <10 points

• Unwilling to take study medications or follow study protocol

• Inability to independently perform Katz Activities of Daily Living (ADLs),

• Allergies to Dasatinib or Quercetin,

• Hospitalization within 6 months,

• Unstable coronary artery disease (myocardial infarction within 6 months or angina),

• Stroke or transient ischemic attack in the past 6 months,

• Chronic heart failure,

• Current or chronic history of liver disease,

• Neurodegenerative disease including Parkinson's disease,

• Anemia,

• Chronic renal disease,

• Drug or alcohol abuse in the last 5 years,

• QTc prolongation,

• Thrombocytopenia,

• Neutropenia,

• Prolonged prothrombin time or INR,

• Indications of current fluid retention,

• History or current diagnosis of pulmonary hypertension,

• Inability to insonate the middle cerebral artery through a temporal bone window on at least one side using transcranial Doppler ultrasound, or

• Chronic use of any of the following medications: anti-arrhythmic medications, antipsychotics, anxiolytics, anti-platelet or anti-coagulant medications other than aspirin, quinolone antibiotics, or drugs metabolized by the same liver enzymes as Quercetin or Dasatinib.